TCP is not an ideal therapeutic agent because it lacks specificity for LSD1; it was originally approved by the United States Food and Drug Administration (FDA) for the treatment of depression based on its ability to inhibit monoamine oxidase (MAO). The gene discussed is KDM1A; the disease is depressive symptom measurement.